Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,500 | |||
2 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 16,500 | |||
10 mg | 在庫あり | ¥ 26,000 | |||
25 mg | 在庫あり | ¥ 55,000 | |||
50 mg | 在庫あり | ¥ 80,000 | |||
100 mg | 在庫あり | ¥ 123,500 | |||
200 mg | 在庫あり | ¥ 176,500 |
説明 | Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots. |
分子量 | 1322 |
分子式 | C42H59N3Na4O35S2 |
CAS No. | 679809-58-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Insoluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Enoxaparin sodium 679809-58-6 Proteases/Proteasome Thrombin traumatic brain injury infection coronavirus Inhibitor PK-10169 inhibit SARS-CoV Enoxaparin neuroprotective Liver fibrosis Fxa PK 10169 Inflammation PK10169 SARS coronavirus acute coronary syndromes Factor Xa Lovenox blood clots COVID-19 Thioacetamide inhibitor